John M. Pagel
Acting Instructor, University of Washington, Department of Medicine, Division of Oncology, 2005.
Associate in Clinical Research, Fred Hutchinson Cancer Research Center, 2002.
Senior Fellow, Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, 1999.
Internal Medicine Residency, University of California, San Francisco, Department of Medicine, 1999.
Internal Medicine Internship, University of California, San Francisco, Department of Medicine, 1997.
M.D., Magna cum laude, Boston University, School of Medicine, 1996.
Post-doctoral, University of California, San Francisco, Howard Hughes Research Associate, 1992.
Ph.D., University of California, Irvine, Microbiology and Molecular Genetics, 1991.
Dr. Pagel leads leukemia studies of radioimmunotherapy at the Center as the principal investigator of several human clinical trials. He is working to increase the usefulness of antibody therapy by "pretargeting" radiation directly to the cells. He is also researching nonradioactive chemical partners to antibodies.
American Society for Blood and Marrow Transplantation
American Society of Hematology
European Association of Nuclear Medicine
Puget Sound Oncology Consortium
Honors and Awards
2005, Clinical Investigator Award, Damon Runyon Cancer Research Foundation
2004, Career Development Award, Lymphoma Research Foundation
2004, Career Development Award, ASCO
2002, Young Investigator Award, ASCO
1994, Pathology Honor Society, Assoc. of Pathology Chairs, BU School of Medicine
1994, Alpha Omega Alpha Medical Honor Society, BU School of Medicine
1993, Family Medicine Interest Gr. Leadership Award, Am. Academy of Family Physicians
1991-1992, Howard Hughes Post-doctoral Research Award, UCSF
1988-1991, National Institutes of Health Pre-doctoral Fellow, UC Irvine
1986, Univ. of California Undergraduate Research Award, UC Riverside
1985, University of California Presidents Award, UC Riverside
1982, Bank of America Academic Leadership Award, UCLA
1982-1986, Mountains Community Hospital Health Profession Scholarship, UCLA
1982, University of California Chancellor's Scholarship, UCLA
1982-1983, Ralph J. Bunche Academic Scholarship, UCLA
Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.. British journal of haematology. 172(1):134-136.. 2016.
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.. British journal of haematology. 172(2):238-245.. 2016.
Alpha Imaging Confirmed Efficient Targeting of CD45-Positive Cells after Astatine-211 (211At)-Radioimmunotherapy for Hematopoietic Cell Transplantation.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine.. 2015.
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.. British journal of haematology.. 2015.
Management of adverse events associated with idelalisib treatment: expert panel opinion.. Leukemia & lymphoma. :1-8.. 2015.
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.. American journal of hematology. 90(6):483-6.. 2015.
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.. Leukemia & lymphoma. 56(1):92-6.. 2015.
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(2):281-7.. 2015.
Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(2):373-8.. 2015.
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(11):1258-64.. 2015.
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.. American journal of hematology. 90(4):295-300.. 2015.
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(9):1363-8.. 2014.
In vivo localization of 90Y and 177Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.. Cancer research. 74(20):5846-54.. 2014.
Factors associated with early re-induction chemotherapy for adults with acute myeloid leukemia.. Leukemia & lymphoma. :1-10.. 2014.